Cargando…

Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

BACKGROUND: There are numerous reports describing the efficacy of fenofibrate in combination with ezetimibe for treating dyslipidemia. In contrast, a study combining bezafibrate and ezetimibe has not yet been conducted. In this study, we examined the safety, including the risk of gallstone formation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teramoto, Tamio, Abe, Kazunori, Taneyama, Takehiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226247/ https://www.ncbi.nlm.nih.gov/pubmed/24195788 http://dx.doi.org/10.1186/1475-2840-12-163

Ejemplares similares

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
por: Teramoto, Tamio, et al.
Publicado: (2012)

Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial
por: Arbel, Yaron, et al.
Publicado: (2016)

Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights
por: Chilbert, Maya R, et al.
Publicado: (2022)

Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
por: Yamaoka-Tojo, Minako, et al.
Publicado: (2009)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

The Efficacy and Safety of Ezetimibe and Low-Dose Simvastatin as a Primary Treatment for Dyslipidemia in Renal Transplant Recipients
por: Yoon, Hye Eun, et al.
Publicado: (2009)

Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease
por: Tadiboyina, Venu T, et al.
Publicado: (2005)

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study
por: Ohno, Yuko, et al.
Publicado: (2014)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy
por: Grandi, Anna M, et al.
Publicado: (2014)

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
por: Node, Koichi, et al.
Publicado: (2009)

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
por: Tenenbaum, Alexander, et al.
Publicado: (2008)

Ezetimibe Monotherapy Reduces Serum Levels of Platelet-Activating Factor Acetylhydrolase in Patients With Dyslipidemia
por: Tano, Kanako, et al.
Publicado: (2019)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients
por: Rodríguez-Saldaña, Joel, et al.
Publicado: (2022)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease
por: Kovach, Christopher P., et al.
Publicado: (2023)

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
por: Ida, Satoshi, et al.
Publicado: (2019)

I-3 Treatment of CPT2 deficiency with bezafibrate
por: Laforet, P.
Publicado: (2011)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
por: Kim, Ju-Yeon, et al.
Publicado: (2021)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Long-Term Bezafibrate Treatment Improves Skin and Spleen Phenotypes of the mtDNA Mutator Mouse
por: Dillon, Lloye M., et al.
Publicado: (2012)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

Obesity and dyslipidemia in patients with psoriasis treated at a dermatologic clinic in Manaus
por: Santos, Mônica, et al.
Publicado: (2013)

Investigation of novel material for effective photodegradation of bezafibrate in aqueous samples
por: Regulska, Elżbieta, et al.
Publicado: (2014)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017)

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency
por: Suyama, Tomonori, et al.
Publicado: (2020)

Bezafibrate Reduces Elevated Hepatic Fumarate in Insulin-Deficient Mice
por: Franko, Andras, et al.
Publicado: (2022)

Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial
por: Vattimo, Antonio Carlos Amedeo, et al.
Publicado: (2020)

Distinctive Gut Microbiota in Patients with Overweight and Obesity with Dyslipidemia and its Responses to Long-term Orlistat and Ezetimibe Intervention: A Randomized Controlled Open-label Trial
por: Jin, Jin, et al.
Publicado: (2021)

The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
por: Wan, Shuling, et al.
Publicado: (2021)

Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)
por: Bardini, Gianluca, et al.
Publicado: (2010)

Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy
por: Camargo, L.M., et al.
Publicado: (2014)

Effectiveness and Safety of Different Vascular Closure Devices: Multicentre Prospective Observational study
por: Ierardi, Anna Maria, et al.
Publicado: (2023)

Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial
por: Leyes, Pere, et al.
Publicado: (2014)

Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
por: Oikawa, Shinichi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3bh63d9mq4m89koefpjmo56r8f